QIA Stock Chart & Stats
€36.34
€0.19(0.51%)
At close: 4:00 PM EDT
€36.34
€0.19(0.51%)
Day’s Range― - ―
52-Week Range€27.56 - €47.60
Previous CloseN/A
Volume589.71K
Average Volume (3M)757.07K
Market Cap
€7.47B
Enterprise Value€8.98K
Total Cash (Recent Filing)€793.50M
Total Debt (Recent Filing)€1.64B
Price to Earnings (P/E)22.8
Beta0.37
Next Earnings
Nov 10, 2026EPS Estimate
0.54Next Dividend Ex-DateN/A
Dividend Yield11.42%
Share Statistics
EPS (TTM)1.95
Shares Outstanding206,074,750
10 Day Avg. Volume664,167
30 Day Avg. Volume757,073
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.61
Price to Sales (P/S)4.71
P/FCF Ratio21.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€37.73Price Target Upside3.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)2.1
Revenue Forecast (FY)€1.85B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelConsumables purchased per test or laboratory run create repeat revenue and improve customer retention. The installed instrument base further supports long-lived pull-through demand, making the model less dependent on one-time equipment sales.
Diagnostic Portfolio ExpansionFDA clearance broadens QIAGEN’s addressable diagnostic market and strengthens QIAstat-Dx’s clinical utility. The platform’s global placements and expanded infectious-disease menu can support recurring assay demand and future customer adoption.
Strong Cash GenerationRobust operating and free cash flow provide internal funding for research, product launches, dividends and other capital allocation. This supports strategic flexibility and reduces reliance on external financing as the company expands its portfolio.
Bears Say
Uneven Growth And MarginsThe uneven multi-year trajectory indicates that demand, product mix and execution can materially affect results. Although profitability has recovered, prior volatility and slight margin compression make the sustainability of current earnings less certain.
Category And Regional WeaknessWeakness in important diagnostic and amplification categories, alongside China and broader regional softness, can constrain near-term growth. Persistent mix and geographic pressure could delay operating leverage and require greater investment to restore momentum.
Leadership And Strategic UncertaintyA leadership transition and ongoing strategic review may slow decision-making or alter capital allocation and portfolio priorities. Until direction is clearer, execution risk is higher and customers, employees and investors may face less visibility.
Qiagen News
QIA FAQ
What was Qiagen’s price range in the past 12 months?
Qiagen lowest stock price was €27.56 and its highest was €47.59 in the past 12 months.
What is Qiagen’s market cap?
Qiagen’s market cap is €7.47B.
When is Qiagen’s upcoming earnings report date?
Qiagen’s upcoming earnings report date is Nov 10, 2026 which is in 82 days.
How were Qiagen’s earnings last quarter?
Qiagen released its earnings results on Aug 05, 2026. The company reported €0.537 earnings per share for the quarter, beating the consensus estimate of €0.518 by €0.019.
Is Qiagen overvalued?
According to Wall Street analysts Qiagen’s price is currently Undervalued.
Does Qiagen pay dividends?
Qiagen pays a Semiannually dividend of €0.3 which represents an annual dividend yield of 11.42%. See more information on Qiagen dividends here
What is Qiagen’s EPS estimate?
Qiagen’s EPS estimate is 0.54.
How many shares outstanding does Qiagen have?
Qiagen has 206,074,750 shares outstanding.
What happened to Qiagen’s price movement after its last earnings report?
Qiagen reported an EPS of €0.537 in its last earnings report, beating expectations of €0.518. Following the earnings report the stock price went down -0.632%.
Which hedge fund is a major shareholder of Qiagen?
Currently, no hedge funds are holding shares in DE:QIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Qiagen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€37.73 (3.81% Upside)
€37.73 (3.81% Upside)
Blogger Sentiment
Bullish
DE:QIA Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €848.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.65%
12-Months-Change
Fundamentals
Return on Equity
11.42%
Trailing 12-Months
Asset Growth
4.27%
Trailing 12-Months
Company Description
Qiagen
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
QIA Company Deck
QIA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive: management reported results above outlook for sales and adjusted EPS, strong cash generation, high profitability, and clear momentum in key growth pillars (Sample Technologies, QIAcuity, QDI) alongside active product launches and capital returns (40% dividend increase, $500M repurchase). Challenges include declines in QIAstat and PCR product groups, China and regional softness, a notable revenue loss from reduced immigration testing (~$35M) affecting QuantiFERON comparisons, modest margin and inventory pressures, and ongoing strategic/leadership transition that creates near-term uncertainty. On balance, the company emphasized confidence in a stronger second half of 2026 driven by new product rollouts and easing comparables.View all DE:QIA earnings summariesQIA Stock 12 Month Forecast
Average Price Target
€37.73
▲(3.81% Upside)